OPK 0018

Drug Profile

OPK 0018

Alternative Names: OPK-0018

Latest Information Update: 11 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Unknown
  • Developer OPKO Health
  • Class Antiasthmatics; Oligosaccharides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 31 Jan 2016 Discontinued - Preclinical for Asthma and Chronic obstructive pulmonary disease in USA (PO & Inhalation)
  • 10 Jan 2011 Phase-I clinical trials in Asthma in USA (Inhalation)
  • 10 Jan 2011 Phase-I clinical trials in Asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top